Intraocular injection of tamoxifen‐loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis

In this study, we tested the efficiency of an intravitreal injection of tamoxifen, a non‐steroidal estrogen receptor modulator, in retinal soluble antigen (S‐Ag)‐induced experimental autoimmune uveoretinitis (EAU). To increase the bioavailability of tamoxifen, we incorporated tamoxifen into polyethylene glycol (PEG)‐coated nanoparticles (NP‐PEG‐TAM). The localization of the nanoparticles within the eye was investigated using fluorescent‐labeled PEG‐coated nanoparticles after injection into the vitreous cavity of rats with EAU. Some nanoparticles were distributed extracellularly throughout the ocular tissues, others were concentrated in resident ocular cells and in infiltrating macrophages. Whereas the injection of free tamoxifen did not alter the course of EAU, injection of NP‐PEG‐TAM performed 1–2 days before the expected onset of the disease in controls resulted in significant inhibition of EAU. NP‐PEG‐TAM injection significantly reduced EAU compared to injection of NP‐PEG‐TAM with 17β‐estradiol (E2), suggesting that tamoxifen is acting as a partial antagonist to E2. Diminished infiltration by MHC class II+ inflammatory cells and low expression of TNF‐α, IL‐1β, and RANTES mRNA were noted in eyes of NP‐PEG‐TAM‐treated rats. Intravitreal injection of NP‐PEG‐TAM decreased S‐Ag lymphocyte proliferation, IFN‐γ production by inguinal lymph node cells, and specific delayed‐type hypersensitivity indicative of a reduced Th1‐type response. It increased the anti‐S‐Ag IgG1 isotype indicating an antibody class switch to Th2 response. These data suggest that NP‐PEG‐TAM inhibition of EAU could result from a form of immune deviation. Tamoxifen‐loaded nanoparticles may represent a new option for the treatment of experimental uveitis.